Ver el código de «Template:Crofab dosing»

===Initial Administration===
*Initial dose: 6 vials<ref>Gerardo CJ. The efficacy of crotalidea polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled, clinical trial. Annals of EM. August 2017. 70(2):233-244.</ref>
*Typically diluted into 250 cc or 1 L of normal saline and infused over an hour
*Same dose for both adults and pediatrics (may have to adjust the dilution of CroFab for small children so that they are not volume overloaded)

===Maintenance therapy===
*May repeat dose (2 vials) at 6, 12, and 18 hours later if symptoms not controlled<ref>Gerardo CJ. The efficacy of crotalidea polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled, clinical trial. Annals of EM. August 2017. 70(2):233-244.</ref>
**''Maintance therapy may be indicated after initial dosing based on local protocols even if control is achieved.<ref>Crofab treatment agorithmn http://www.crofab.com/documents/CroFab-Treatment_Algorithm.pdf</ref>

===Envenomation control measurement===
*Observe for progression of envenomation during and after antivenom infusion
*Measure limb circumference at several sites above and below bite
*Mark advancing border of edema q30min
*Repeat labs q4hr or after each course of antivenom (whichever is more frequent)

===Side Effects===
*Acute [[allergic reactions]] occur in <10% pts
**If occurs stop infusion and give epinephrine/antihistamines if needed
*Recurrent [[thrombocytopenia]] has been described up to 2 weeks after transfusion with FabAV and is likely a result of isolated renal clearance of FabAV and persistent presence of actual venom in serum.<ref>Ruha AM et al. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom. Toxicon. 2011;57:53–59.</ref>
**Warrants close monitoring of platelets by primary physician or return visit after discharge
*[[Serum sickness]] is unlikely but precautions should be given to patents upon discharge